Longeveron Inc. (NASDAQ:LGVN) CEO Mohamed Wa’el Ahmed Hashad Buys 10,638 Shares

Longeveron Inc. (NASDAQ:LGVN) CEO Mohamed Wa’el Ahmed Hashad bought 10,638 shares of the firm’s stock in a transaction dated Thursday, April 11th. The stock was purchased at an average cost of $2.35 per share, with a total value of $24,999.30. Following the transaction, the chief executive officer now directly owns 19,616 shares in the company, valued at approximately $46,097.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Longeveron Stock Performance

Shares of Longeveron stock opened at $1.69 on Friday. Longeveron Inc. has a 12 month low of $1.62 and a 12 month high of $44.00. The firm has a market capitalization of $4.25 million, a P/E ratio of -0.17 and a beta of 0.21. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.21. The business has a fifty day simple moving average of $4.32 and a two-hundred day simple moving average of $12.35.

Longeveron (NASDAQ:LGVN) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($2.50) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.40). The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.21 million. Longeveron had a negative return on equity of 209.14% and a negative net margin of 3,020.17%. On average, equities analysts forecast that Longeveron Inc. will post -8.5 earnings per share for the current fiscal year.

Institutional Trading of Longeveron

Several hedge funds and other institutional investors have recently made changes to their positions in LGVN. Citadel Advisors LLC bought a new stake in Longeveron in the fourth quarter worth $44,000. Northern Trust Corp purchased a new stake in Longeveron during the 2nd quarter valued at about $63,000. State Street Corp bought a new stake in Longeveron during the 2nd quarter valued at about $88,000. Geode Capital Management LLC raised its holdings in Longeveron by 78.6% in the second quarter. Geode Capital Management LLC now owns 66,392 shares of the company’s stock worth $224,000 after buying an additional 29,212 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new position in shares of Longeveron in the second quarter worth approximately $254,000. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.